Re. Willburger et al., ANTIINFLAMMATORY EFFECT OF TEPOXALIN - BLOOD AND SYNOVIAL TISSUE STUDIED IN PATIENTS WITH KNEE ARTHROSIS, Acta orthopaedica Scandinavica, 69(3), 1998, pp. 295-300
Our aim was to determine the amounts of eicosanoids in blood and synov
ial tissue of patients with knee arthrosis and to examine the effects
of 2 doses of tepoxalin (50 mg twice, 200 mg twice), administered p.o.
for 3.5 days. Concentrations of leukotriene B-4 (LTB4), LTC4, and thr
omboxane B-2 (TXB2) were measured in blood before and after oral admin
istration of tepoxalin and release of prostaglandin E-2, (PGE(2)), 6-k
eto-PGF(1alpha), and LTC4 was measured in incubation media of synovial
tissue, taken at surgery from patients treated with tepoxalin, Radioi
mmunoassay (RIA) was used to determine the levels of the eicosanoids.
LT and TXB2, release was reduced by tepoxalin in both doses used. Unde
r these conditions, PGE(2), 6-keto-PGF(1alpha), and LTC4 release from
synovial tissue was detectable only after stimulation with calcium ion
ophore A23187. Washed synovial tissue, in which tepoxalin concentratio
ns should be reduced, released higher amounts of all eicosanoids measu
red than directly incubated synovial tissue did. Pain after tepoxalin
administration was significantly reduced. Relevant drug concentrations
were detected in plasma and synovial fluid. Tepoxalin was well tolera
ted and had no marked adverse effects. At 400 mg, tepoxalin is a dual
inhibitor of cyclooxygenase (CO) and 5-lipoxygenase (5-LO) in blood an
d synovial tissue.